HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alzheimer Disease (Alzheimer's Disease)

A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Also Known As:
Alzheimer's Disease; Senile Dementia; Early Onset Alzheimer Disease; Late Onset Alzheimer Disease; Primary Senile Degenerative Dementia; Presenile Dementia; Alzheimer Dementia; Alzheimer Disease, Early Onset; Alzheimer Disease, Late Onset; Alzheimer Sclerosis; Alzheimer Syndrome; Alzheimer Type Senile Dementia; Alzheimer's Disease, Focal Onset; Alzheimer-Type Dementia (ATD); Dementia, Presenile; Dementia, Primary Senile Degenerative; Familial Alzheimer Disease (FAD); Focal Onset Alzheimer's Disease; Senile Dementia, Acute Confusional; Alzheimer Dementias; Alzheimer Disease, Familial (FAD); Alzheimer Diseases; Alzheimer Type Dementia; Alzheimer Type Dementia (ATD); Alzheimers Diseases; Dementia, Alzheimer; Dementia, Alzheimer-Type (ATD); Familial Alzheimer Diseases (FAD); Sclerosis, Alzheimer; Acute Confusional Senile Dementia; Alzheimer's Diseases; Dementia, Alzheimer Type; Dementia, Senile; Presenile Alzheimer Dementia; Senile Dementia, Alzheimer Type
Networked: 91974 relevant articles (3655 outcomes, 11690 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Cognitive Dysfunction
2. Dementia (Dementias)
3. Parkinson Disease (Parkinson's Disease)
4. Neurodegenerative Diseases (Neurodegenerative Disease)
5. Neuroinflammatory Diseases

Experts

1. Blennow, Kaj: 741 articles (11/2022 - 03/2000)
2. Zetterberg, Henrik: 710 articles (11/2022 - 07/2003)
3. Alzheimer’s Disease Neuroimaging Initiative: 467 articles (11/2022 - 09/2010)
4. Alzheimer's Disease Neuroimaging Initiative: 447 articles (07/2022 - 11/2008)
5. Masters, Colin L: 341 articles (11/2022 - 01/2002)
6. Scheltens, Philip: 310 articles (10/2022 - 08/2002)
7. Trojanowski, John Q: 287 articles (10/2022 - 02/2002)
8. Holtzman, David M: 269 articles (02/2022 - 03/2002)
9. Morris, John C: 259 articles (10/2022 - 02/2002)
10. Perry, George: 255 articles (01/2022 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Alzheimer Disease:
1. Amyloid (Amyloid Fibrils)IBA
2. Amyloid beta-PeptidesIBA
3. Cholinesterase Inhibitors (Anticholinesterases)IBA
4. Donepezil (Aricept)FDA LinkGeneric
01/01/2004 - "Despite a sense of limited efficacy of this drug class among prescribers, number needed-to-treat analyses suggest donepezil is highly effective at reducing the long-term adverse outcomes associated with Alzheimer's disease."
10/01/2000 - "There have been a number of randomised, placebo-controlled trials of donepezil in the treatment of mild-moderate Alzheimer's disease and these report significant benefits for a proportion of patients. "
03/01/2000 - "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease. "
08/20/2017 - "Objective To explore the efficacy of ganoderma lucidum preparation(Ling Zhi) in treating APP/PS-1 transgenic mouse models of Alzheimer's disease(AD).Methods APP/PS-1 transgenic mice of 4 months were randomly divided into model group,ganoderma lucidum treatment groups,including high [2250 mg/(kg·d)] and middle [750 mg/(kg·d)] dose groups,i.e.LZ-H and LZ-M groups,and the positive control group(treated with donepezil hydrochloride [2 mg/(kg·d)]).In addition,C57BL/6J wild mice were selected as normal group.The"
06/20/2017 - "Objective To evaluate the efficacy of Ganoderma lucidum preparation on the behaviors,biochemistry,and autoimmunity parameters of mouse models of APP/PS-1 double transgenic Alzheimer's disease(AD).Methods A total of 44 4-month-old APP/PS-1 double transgenic AD mice were randomly divided into AD model group,Aricept group,Ganoderma lucidum middle-dose(LZ-M)group,and Ganoderma lucidum high-dose(LZ-H)group,with 11 mice in each group.In"
5. Peptides (Polypeptides)IBA
6. Proteins (Proteins, Gene)FDA Link
7. Biomarkers (Surrogate Marker)IBA
8. Memantine (Namenda)FDA Link
9. Cholinergic Agents (Cholinergics)IBA
10. Rivastigmine (Exelon)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Immunotherapy
3. Activities of Daily Living (ADL)
4. Cognitive Training
5. Transcranial Magnetic Stimulation